Twist Bioscience CFO sells shares for tax withholding

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share.

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans, and were not discretionary trades. After this transaction, Laponis directly holds 125,694 shares of Twist Bioscience common stock.

Insider Trade Summary

Net Seller: 2,597 shares

Net Sell 1 txn

Insider Laponis Adam

Role Chief Financial Officer

Sold 2,597 shs ($130K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,597	$49.889	$130K

Holdings After Transaction: Common Stock — 125,694 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Key Figures

Shares sold: 2,597 shares Sale price: $49.889 per share Shares held after transaction: 125,694 shares

3 metrics

Shares sold 2,597 shares Open-market sale on April 9, 2026

Sale price $49.889 per share Average price for shares sold to cover taxes

Shares held after transaction 125,694 shares Direct holdings of CFO Adam Laponis after sale

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"to be funded by a "sell to cover" transaction and do not"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"the Issuer's election under its equity incentive plans to require"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report for its CFO?

Twist Bioscience reported that CFO Adam Laponis sold 2,597 shares of common stock at $49.889 per share. The sale covered tax withholding obligations from Restricted Stock Unit vesting under the company’s equity incentive plans, rather than representing a discretionary market trade.

Why did Twist Bioscience CFO Adam Laponis sell 2,597 TWST shares?

The 2,597 shares were sold to satisfy tax withholding obligations from vesting Restricted Stock Units. The company’s equity plans mandate a "sell to cover" approach, so these sales are automatic for tax purposes and do not reflect a discretionary investment decision by the CFO.

At what price were the Twist Bioscience (TWST) shares sold in this Form 4?

The shares were sold at an average price of $49.889 per share. This price applies to the 2,597 shares sold by CFO Adam Laponis to cover tax withholding obligations related to the vesting of his Restricted Stock Units on April 9, 2026.

How many Twist Bioscience (TWST) shares does the CFO hold after this tax-related sale?

Following the transaction, CFO Adam Laponis directly holds 125,694 shares of Twist Bioscience common stock. The 2,597 shares sold represented only the amount needed for tax withholding, so he continues to retain a substantial direct equity position in the company.

Is the Twist Bioscience CFO’s recent share sale considered a discretionary trade?

No. The filing specifies the sale was mandated to cover tax withholding on Restricted Stock Unit vesting. Under the company’s equity incentive plans, these "sell to cover" transactions occur automatically and are not discretionary trading decisions by the reporting officer.

What type of security was involved in the Twist Bioscience CFO Form 4 filing?

The transaction involved common stock of Twist Bioscience Corp. The shares were sold to fund taxes associated with vesting Restricted Stock Units, which are equity awards granted under the company’s equity incentive plans and settle into common shares upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/09/2026		S		2,597(1)	D	$49.889	125,694	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)